This is an application for competitive renewal of K-series career award support for years 21-25. The focus of the applicant's research career is on the human behavioral pharmacology of drug abuse. The applicant directs a large and multi faceted clinical research program that includes two major components: (1) residential human laboratory studies related to the clinical pharmacology of opioids, of cocaine, and of potential pharmacotherapies for opioid or cocaine dependence; and (2) outpatient controlled clinical trials of behavioral and pharmacological treatments for opioid or cocaine dependence. The research program is also the site of a postdoctoral research training program, which has a history of training productive new scientists as drug abuse researchers, and of which the applicant is director. The applicant proposes to continue as research program director, and as training program director, and to conduct during this renewal period an inter-related series of human laboratory studies and outpatient clinical trials directed toward the behavioral pharmacological understanding and treatment of opioid and cocaine abuse. The opioid clinical pharmacology studies will evaluate the effects of opioids with kappa-receptor agonist activity in comparison to mu-receptor agonists, and will assess and characterize the effects of an opioid antagonist combination product (buprenorphine plus naloxone) that is being developed as an opioid dependence pharmacotherapy. The cocaine clinical pharmacology studies will test potential anti-cocaine pharmacotherapies by assessing whether response to cocaine challenge is altered by pretreatment with various agents (chronic oral cocaine, the opioid kappa agonist enadoline, the serotonergic agent tryptophan). The opioid dependence clinical trials will compare the efficacy and patient acceptability of three opioid agonist substitution pharmacotherapies (methadone, LAAM, buprenorphine). The cocaine dependence clinical trials will evaluate the efficacy of the serotonergic agents tryptophan and fluoxetine in the context of an incentive-based behavior therapy program.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Scientist Award (K05)
Project #
5K05DA000050-23
Application #
6137768
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Montoya, Ivan
Project Start
1993-01-01
Project End
2002-12-31
Budget Start
2000-01-01
Budget End
2000-12-31
Support Year
23
Fiscal Year
2000
Total Cost
$124,416
Indirect Cost
Name
Johns Hopkins University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Copersino, Marc L; Meade, Christina S; Bigelow, George E et al. (2010) Measurement of self-reported HIV risk behaviors in injection drug users: comparison of standard versus timeline follow-back administration procedures. J Subst Abuse Treat 38:60-5
Rogers, Randall E; Higgins, Stephen T; Silverman, Kenneth et al. (2008) Abstinence-contingent reinforcement and engagement in non-drug-related activities among illicit drug abusers. Psychol Addict Behav 22:544-50
Wedam, Erich F; Bigelow, George E; Johnson, Rolley E et al. (2007) QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 167:2469-75
Sigmon, Stacey C (2007) Investigating the pharmacological and nonpharmacological factors that modulate drug reinforcement. Exp Clin Psychopharmacol 15:1-20
Sigmon, Stacey C; Moody, David E; Nuwayser, Elie S et al. (2006) An injection depot formulation of buprenorphine: extended bio-delivery and effects. Addiction 101:420-32
Lott, David C; Strain, Eric C; Brooner, Robert K et al. (2006) HIV risk behaviors during pharmacologic treatment for opioid dependence: a comparison of levomethadyl acetate [corrected] buprenorphine, and methadone. J Subst Abuse Treat 31:187-94
Carroll, C Patrick; Walsh, Sharon L; Bigelow, George E et al. (2006) Assessment of agonist and antagonist effects of tramadol in opioid-dependent humans. Exp Clin Psychopharmacol 14:109-20
Donny, Eric C; Bigelow, George E; Walsh, Sharon L (2006) Comparing the physiological and subjective effects of self-administered vs yoked cocaine in humans. Psychopharmacology (Berl) 186:544-52
Lofwall, Michelle R; Brooner, Robert K; Bigelow, George E et al. (2005) Characteristics of older opioid maintenance patients. J Subst Abuse Treat 28:265-72
Donny, Eric C; Brasser, Susan M; Bigelow, George E et al. (2005) Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. Addiction 100:1496-509

Showing the most recent 10 out of 65 publications